OBJECTIVE: Excess weight has been associated with increased risk of cancer at several organ sites. In part, this effect may be modulated through alterations in the metabolism of sex steroids and IGF-I related peptides. The objectives of the study were to examine the association of body mass index (BMI) with circulating androgens (testosterone, androstenedione and dehydroepiandrosterone sulfate (DHEAS)), estrogens (estrone and estradiol), sex hormone-binding globulin (SHBG), IGF-I and IGF-binding protein (IGFBP)-3, and the relationship between sex steroids, IGF-I and IGFBP-3. DESIGN AND METHODS: A cross-sectional analysis was performed using hormonal and questionnaire data of 620 healthy women (177 pre- and 443 post-menopausal). The laboratory measurements of the hormones of interest were available from two previous case-control studies on endogenous hormones and cancer risk. RESULTS: In the pre-menopausal group, BMI was not related to androgens and IGF-I. In the post-menopausal group, estrogens, testosterone and androstenedione increased with increasing BMI. The association with IGF-I was non-linear, with the highest mean concentrations observed in women with BMI between 24 and 25. In both pre- and post-menopausal subjects, IGFBP-3 did not vary across BMI categories and SHBG decreased with increasing BMI. As for the correlations between peptide and steroid hormones, in the post-menopausal group, IGF-I was positively related to androgens, inversely correlated with SHBG, and not correlated with estrogens. In the pre-menopausal group, similar but weaker correlations between IGF-I and androgens were observed. CONCLUSIONS: These observations offer evidence that obesity may influence the levels of endogenous sex-steroid and IGF-related hormones in the circulation, especially after menopause. Circulating IGF-I, androgens and SHBG appear to be related to each other in post-menopausal women.
OBJECTIVE: Excess weight has been associated with increased risk of cancer at several organ sites. In part, this effect may be modulated through alterations in the metabolism of sex steroids and IGF-I related peptides. The objectives of the study were to examine the association of body mass index (BMI) with circulating androgens (testosterone, androstenedione and dehydroepiandrosterone sulfate (DHEAS)), estrogens (estrone and estradiol), sex hormone-binding globulin (SHBG), IGF-I and IGF-binding protein (IGFBP)-3, and the relationship between sex steroids, IGF-I and IGFBP-3. DESIGN AND METHODS: A cross-sectional analysis was performed using hormonal and questionnaire data of 620 healthy women (177 pre- and 443 post-menopausal). The laboratory measurements of the hormones of interest were available from two previous case-control studies on endogenous hormones and cancer risk. RESULTS: In the pre-menopausal group, BMI was not related to androgens and IGF-I. In the post-menopausal group, estrogens, testosterone and androstenedione increased with increasing BMI. The association with IGF-I was non-linear, with the highest mean concentrations observed in women with BMI between 24 and 25. In both pre- and post-menopausal subjects, IGFBP-3 did not vary across BMI categories and SHBG decreased with increasing BMI. As for the correlations between peptide and steroid hormones, in the post-menopausal group, IGF-I was positively related to androgens, inversely correlated with SHBG, and not correlated with estrogens. In the pre-menopausal group, similar but weaker correlations between IGF-I and androgens were observed. CONCLUSIONS: These observations offer evidence that obesity may influence the levels of endogenous sex-steroid and IGF-related hormones in the circulation, especially after menopause. Circulating IGF-I, androgens and SHBG appear to be related to each other in post-menopausal women.
Authors: Shawn E Nielsen; Sarah J Barber; Audrey Chai; David V Clewett; Mara Mather Journal: Psychoneuroendocrinology Date: 2015-08-04 Impact factor: 4.905
Authors: Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte Journal: Int J Cancer Date: 2018-02-08 Impact factor: 7.396
Authors: A Heather Eliassen; Regina G Ziegler; Lauren C Houghton; Julia S Sisti; Susan E Hankinson; Jing Xie; Xia Xu; Robert N Hoover Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-06 Impact factor: 4.254
Authors: Christy G Woolcott; Kerry S Courneya; Norman F Boyd; Martin J Yaffe; Tim Terry; Anne McTiernan; Rollin Brant; Rachel Ballard-Barbash; Melinda L Irwin; Charlotte A Jones; Sony Brar; Kristin L Campbell; Margaret L McNeely; Kristina H Karvinen; Christine M Friedenreich Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Kim N Danforth; A Heather Eliassen; Shelley S Tworoger; Stacey A Missmer; Robert L Barbieri; Bernard A Rosner; Graham A Colditz; Susan E Hankinson Journal: Int J Cancer Date: 2010-01-01 Impact factor: 7.396
Authors: Renate M Winkels; Kathleen M Sturgeon; Michael J Kallan; Lorraine T Dean; Zi Zhang; Margaret Evangelisti; Justin C Brown; David B Sarwer; Andrea B Troxel; Crystal Denlinger; Monica Laudermilk; Anna Fornash; Angela DeMichele; Lewis A Chodosh; Kathryn H Schmitz Journal: Contemp Clin Trials Date: 2017-07-21 Impact factor: 2.226
Authors: Catherine Duggan; Ching-Yun Wang; Marian L Neuhouser; Liren Xiao; Ashley Wilder Smith; Kerryn W Reding; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Rachel Ballard-Barbash; Anne McTiernan Journal: Int J Cancer Date: 2012-09-01 Impact factor: 7.396